Thyroid Eye Disease Market
完整報告名稱與涵蓋範圍
Thyroid Eye Disease Market Size, Share & Trends Analysis Report By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib), By Region, And By Segment Forecasts, 2025-2034
報告摘要
The worldwide Thyroid Eye Disease Market stood at USD 2.26 billion in 2024, and is poised to reach USD 4.02 billion by 2034, recording a CAGR of 6.0% from 2025 through 2034.
The Thyroid Eye Disease sector involves an autoimmune condition that causes eye swelling, bulging, and pain, often linked to graves' disease. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is propelled by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Thyroid Eye Disease Market Snapshot
Chapter 4. Global Thyroid Eye Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034
4.8. Global Thyroid Eye Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Thyroid Eye Disease Industry Trends
Chapter 5. Thyroid Eye Disease Market Segmentation 1: By Marketed Products, Estimates & Trend Analysis
5.1. Market Share By Marketed Products, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Marketed Products:
5.2.1. TEPEZZA (Teprotumumab)
Chapter 6. Thyroid Eye Disease Market Segmentation 2: By Pipeline Drugs, Estimates & Trend Analysis
6.1. Market Share by Pipeline Drugs, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Pipeline Drugss:
6.2.1. VRDN-001
6.2.2. VB421
6.2.3. Batoclimab
6.2.4. Linsitinib
Chapter 7. Thyroid Eye Disease Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. Global Thyroid Eye Disease Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.2.3. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.3. Europe
7.3.1. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.3.3. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.4.3. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.5. Latin America
7.5.1. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.5.3. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.6.3. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Horizon Therapeutics
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Offerings
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Viridian Therapeutics
8.2.3. Pierre Fabre/ACELYRIN
8.2.4. HanAll Biopharma/Harbour BioMed/Immunovant
8.2.5. Sling Therapeutics
8.2.6. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們